Cargando…

The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study

BACKGROUND: Levels of non-neutralising antibodies (AB) to the C5 domain of HIV Env gp120 are inversely related to progression of HIV infection. In this phase I/II clinical study we investigated safety of Vacc-C5, a peptide-based therapeutic vaccine candidate corresponding to C5/gp41(732–744) as well...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brekke, Kristin, Sommerfelt, Maja, Ökvist, Mats, Dyrhol-Riise, Anne Margarita, Kvale, Dag
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366104/ https://www.ncbi.nlm.nih.gov/pubmed/28340570 http://dx.doi.org/10.1186/s12879-017-2316-x

Ejemplares similares

Intranasal Administration of a Therapeutic HIV Vaccine (Vacc-4x) Induces Dose-Dependent Systemic and Mucosal Immune Responses in a Randomized Controlled Trial
por: Brekke, Kristin, et al.
Publicado: (2014)

Regulation of Gag- and Env-Specific CD8(+) T Cell Responses in ART-Naïve HIV-Infected Patients: Potential Implications for Individualized Immunotherapy
por: Prebensen, Christian, et al.
Publicado: (2016)

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption
por: Rockstroh, Jürgen K., et al.
Publicado: (2019)

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer
por: Khasnis, Mukta D., et al.
Publicado: (2016)

P18-14 LB. Vacc-4x HIV p24-like peptide vaccine-associated increase of CD4 T-cells in chronically infected HIV-1 patients on antiretroviral therapy
por: Bengtsson, P, et al.
Publicado: (2009)

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike
por: Lee, Jeong Hyun, et al.
Publicado: (2015)

IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection
por: Tonby, Kristian, et al.
Publicado: (2015)

Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization
por: Kim, Arthur S., et al.
Publicado: (2014)

Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors
por: Lieske, Nora V., et al.
Publicado: (2015)

Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env
por: Schapiro, Hannah M., et al.
Publicado: (2022)

Soluble Markers of the Toll-Like Receptor 4 Pathway Differentiate between Active and Latent Tuberculosis and Are Associated with Treatment Responses
por: Feruglio, Siri L., et al.
Publicado: (2013)

The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection
por: Tonby, Kristian, et al.
Publicado: (2016)

Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infection
por: Feruglio, S L, et al.
Publicado: (2015)

Outgroup emotion processing in the vACC is modulated by childhood trauma and CACNA1C risk variant
por: Krautheim, Johannes T, et al.
Publicado: (2018)

VaccImm: simulating peptide vaccination in cancer therapy
por: von Eichborn, Joachim, et al.
Publicado: (2013)

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates
por: Gao, G, et al.
Publicado: (2012)

C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic
por: Steckbeck, Jonathan D., et al.
Publicado: (2013)

DIAGNOSTIC ACCURACY AND ADDED VALUE OF INFECTION BIOMARKERS IN PATIENTS WITH POSSIBLE SEPSIS IN THE EMERGENCY DEPARTMENT
por: Christensen, Erik E., et al.
Publicado: (2022)

Enhanced Gut-Homing Dynamics and Pronounced Exhaustion of Mucosal and Blood CD4(+) T Cells in HIV-Infected Immunological Non-Responders
por: Lorvik, Kristina Berg, et al.
Publicado: (2021)

The Vaccination Concerns in COVID-19 Scale (VaCCS): Development and validation
por: Hamilton, Kyra, et al.
Publicado: (2022)

Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection
por: Bandawe, Gama P, et al.
Publicado: (2008)

The C5 region of HIV-1 gp120 binds specific
por: Dalgleish, A, et al.
Publicado: (2006)

The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
por: Goll, Johannes B., et al.
Publicado: (2023)

Decentralized Open Platform for Vaccination—A German Example: COVID-19-Vacc
por: Radonjic-Simic, Mirjana, et al.
Publicado: (2021)

Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial
por: Prebensen, Christian, et al.
Publicado: (2017)

Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response
por: Heydarchi, Behnaz, et al.
Publicado: (2016)

Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients
por: Jøntvedt Jørgensen, Marthe, et al.
Publicado: (2021)

Technical note no. 41: MTV 5308 - Drawing No. C-4682-5A
por: Petty, L
Publicado: (1988)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo
por: Tsao, Li-Chung, et al.
Publicado: (2016)

P04-01. Simultaneous enumeration of HIV-1 gp41 Env-specific IgG and IgM antibody-secreting cells with a multiplex B-cell fluorospot assay
por: Bonsignori, M, et al.
Publicado: (2009)

Specific Substitutions in Region V2 of gp120 env confer SHIV Neutralisation Resistance
por: Pisil, Yalcin, et al.
Publicado: (2020)

Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial
por: Huang, Yunda, et al.
Publicado: (2017)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

Development of Immune-Specific Interaction Potentials and Their Application in the Multi-Agent-System VaccImm
por: Woelke, Anna Lena, et al.
Publicado: (2011)

Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies
por: Goll, Johannes B., et al.
Publicado: (2023)

Human Immunodeficiency Virus–Infected Immunological Nonresponders Have Colon-Restricted Gut Mucosal Immune Dysfunction
por: Meyer-Myklestad, Malin Holm, et al.
Publicado: (2020)

Topology of the C-Terminal Tail of HIV-1 gp41: Differential Exposure of the Kennedy Epitope on Cell and Viral Membranes
por: Steckbeck, Jonathan D., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2ukv4l8im7g6lg3968a758bp7o